Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial.

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

In 2021, GSK said the factory was likely to close in 2025 when its contract with Sandoz ceased "in the absence of any other ...

Depressed children should not be prescribed Seroxat because the controversial drug raises the risk of self-harm and suicidal thoughts, says a new report. Experts say the hotly-debated ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and appointments, here’s a quick look at which stocks will be in focus in today ...

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...